PCSK9 and neoplasm: Additionally, the PCSK9 inhibitor combined with CD137 costimulation could slow tumor growth with enhanced recruitment of CD8+ and GzmB+ CD8+ T cells and reduction of Tregs in a syngeneic mouse model, providing a novel perspective of therapeutic strategies for future research and clinical practice.